Cantor Fitzgerald lowers Regeneron stock price target on Eylea concerns
Cantor Fitzgerald has cut its price target on Regeneron, citing concerns around Eylea, the company's flagship anti-VEGF eye drug facing biosimilar and competitive pressure. The PT reduction highlights a structural revenue risk that could weigh on REGN shares as Eylea's contribution to the $14.3B revenue base comes under sustained pressure.
What happened
Cantor Fitzgerald has cut its price target on Regeneron, citing concerns around Eylea, the company's flagship anti-VEGF eye drug facing biosimilar and competitive pressure.
The read · Jul 6
REGN faces a PT cut from Cantor on Eylea concerns — the question is whether Eylea HD and Dupixent growth can offset biosimilar erosion before the 1% top-line growth rate becomes a consensus re-rating event.
Wrong if
A strong Dupixent beat or surprise Eylea HD script acceleration at the next earnings print could quickly invalidate the short and push the stock higher; any M&A or partnership headline would also be a sharp pain trade.
CoverageSource: Investing.com · Published here MON, JUL 6 · 7:34 AM ET · the only report in this recordHow this is decided →
The chart · REGNTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
Cantor Fitzgerald lowered its price target on Regeneron (REGN), pointing specifically to concerns around Eylea (aflibercept), the blockbuster anti-VEGF treatment for wet AMD and other retinal conditions that has historically been one of Regeneron's largest revenue contributors. The downward revision reflects Wall Street's growing unease about Eylea's near-term revenue trajectory as biosimilar competition intensifies and rival therapies like Vabysmo (faricimab) continue to take market share.
Regenerons FY2025 revenue base sits at $14.3B, growing just 1.0% YoY — a deceleration that already hints at the Eylea erosion thesis playing out. Net margins are at 31.4% with diluted EPS of $41.48, so the underlying business remains profitable, but flat top-line growth is a red flag when the stock still carries a meaningful premium to the broader market.
The second-order question is whether Eylea HD (8mg aflibercept) can serve as a credible bridge product — Regeneron has been pushing the higher-dose version to retain patients and physicians ahead of biosimilar AFL entries. Bulls argue the HD formulation and Dupixent's explosive growth trajectory provide enough offset; bears point to the 1% revenue growth figure as evidence the transition is already grinding.
What to watch: the pace of biosimilar AFL market share gains, Vabysmo script trends, and any Dupixent guidance updates that could either offset or underscore the Eylea drag. A soft next earnings print on Eylea net revenue would validate the bear case and likely spark further PT cuts across the street.
The read, in fullWhy it matters
Cantor's PT cut is the latest signal in a building consensus around Eylea headwinds; FY revenue growth of just 1.0% YoY already validates the erosion thesis in the numbers. If Eylea HD uptake fails to show acceleration at the next print, the stock faces multiple compression risk given its still-premium valuation relative to decelerating growth.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written · closes shown from JUL 6 on
Next · what would move this
4-8 weeks, into next earnings print. Follow to be told when one lands.
Since this story · named here, equal weight · 1D EOD+27.4%
JUL 6 · first close after publicationSEP 4
Price context does not establish that the story caused the move.
▲ The case it holds
Dupixent's sustained double-digit growth trajectory and the Eylea HD 8mg formulation provide credible revenue offsets, and at a 31.4% net margin with $41.48 EPS, the company generates substantial cash that could support buybacks underpinning the share price.
▼ The case it breaks
FY revenue growth of just 1.0% YoY — combined with a fresh Cantor PT cut citing Eylea specifically — suggests biosimilar and competitive erosion is already flowing through the income statement, and the market may not yet have fully re-rated the stock for a structurally slower growth profile.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →